By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Singh Biotechnology (SBT) 

3802 Spectrum Boulevard
Suite 115
Tampa  Florida  33612   U.S.A.
Phone: 352-796-3334 Fax: 352-796-3323


Singh Biotechnology (SBT) is a start-up biotech organization established in 2014 which is in the business of discovering and developing unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune and ophthalmic diseases by leveraging our novel technology platform. Using this technology platform, SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest, which are mutated, over expressed, or play an important role in the pathogenesis of disease(s). Currently SBT has one pre-IND stage program for triple negative breast cancer (TNBC) and several programs in various stages of pre-clinical development for inflammatory bowel disease (IBD), age-related macular degeneration (ADM), rheumatoid arthritis (RA), psoriasis, prostate cancer, acute myeloid leukemia (AML), sarcoma, and glioblastoma. SBT is targeting to file an IND for TNBC in early 2017. Singh Biotechnology is a privately held company headquartered in Tampa, Florida.




Founder & CEO: Sunanda Singh, MD, PhD

Chairman of Scientific Advisory Board: Hector J. Gomez, MD, PhD

Vice President of Research: Ashu Parihar

Business Development: Ameeta Patel, MBA

Director of Research and Drug Development: Robin Meray Patel, PhD

Director of Pharmacology & Dermatologic Research: Utpal K. Patel, MD, PhD

Director of Clinical Dermatology: Anjali H. Singh, MD

Key Statistics

Ownership: Private

Web Site: Singh Biotech


Company News